Man, Mosquito, Malaria Vaccine
The a16z Show2 Maj 2021

Man, Mosquito, Malaria Vaccine

Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate "malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in preprint with The Lancet, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A "weapon" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.

So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- Rajeev Venkayya of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and what's left to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?

Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been nearly a century in the making.

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Avsnitt(1000)

When Fintech Meets Social

When Fintech Meets Social

The last financial crisis prompted many consumers to reassess their banking expectations—none more so than millennials and Gen-Z-ers. While revealing one's financial information was once considered ta...

12 Mars 202023min

Innovation Through Software Development and IT

Innovation Through Software Development and IT

One of the recurring themes we talk about a lot on the a16z Podcast is how software changes organizations, and vice versa... More broadly: it’s really about how companies of all kinds innovate with th...

6 Mars 202045min

The Open Source CIO

The Open Source CIO

In 2014, in "Why There Will Never Be Another Red Hat," Peter Levine argued that Red Hat’s open source business model of commercializing support and services was highly difficult to replicate. Instead,...

28 Feb 202020min

Novel Coronavirus Updates: How Healthcare System, Tests Work; More

Novel Coronavirus Updates: How Healthcare System, Tests Work; More

This episode covers the following -- since our previous deep-dive on the novel coronavirus outbreak -- including:practical implications for the U.S. healthcare system given how it works today, and whe...

27 Feb 202021min

Metrics and Mindsets for Retention & Engagement

Metrics and Mindsets for Retention & Engagement

It's "Marketplaces Week" for us at a16z, thanks to our consumer team releasing a new index of the next industry-defining marketplaces, the Marketplace 100.  But what happens as such marketplaces and o...

20 Feb 202033min

Tough Love, Global Diplomacy, and Lessons on Leadership

Tough Love, Global Diplomacy, and Lessons on Leadership

Susan shares how she learned to leverage the characteristics of her personality early in her career as assistant secretary of state [2:05]One of the important conversations Susan had with a mentor tha...

14 Feb 202050min

Building the First CAR T Company

Building the First CAR T Company

with @OzAzamTmunity1, @JorgeCondeBio, and @omnivorousreadCAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias tha...

7 Feb 202028min

Rebel Talent

Rebel Talent

When we think about rebellious behavior in the context of organizations and companies, we tend to think of rebels as trouble-makers, rabble-rousers; in other words, people who make decisions and proce...

4 Feb 202033min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-svart-marknad
svd-tech-brief
badfluence
rss-borsens-finest
uppgang-och-fall
avanzapodden
bathina-en-podcast
fill-or-kill
tabberaset
24fragor
rss-kort-lang-analyspodden-fran-di
rss-dagen-med-di
lastbilspodden
kapitalet-en-podd-om-ekonomi
borsmorgon
rss-inga-dumma-fragor-om-pengar
rss-veckans-trade